Published 2026-03-14
Summary: A US District Judge ruled that Elon Musk’s use of the drug ketamine will be off limits to attorneys for OpenAI and its CEO Sam Altman in an upcoming jury trial related to OpenAI’s nonprofit origins and alleged defrauding claims by Musk.
What We Know
- US District Judge Yvonne Gonzalez Rogers issued a ruling restricting attorneys for OpenAI and Sam Altman from probing Musk’s ketamine use during the forthcoming jury trial.
- The trial involves claims that OpenAI defrauded Musk by abandoning its nonprofit roots; the ketamine detail is limited to evidentiary scope, not a broader medical assessment.
- The information appears to connect Musk’s drug use to procedural rulings in the cited case, as reported by Bloomberg and other outlets.
- Media coverage indicates ketamine use is a point of exclusion for trial attorneys, shaping what evidence can be discussed in court.
- Public reporting places the development within the context of OpenAI v. Musk-related litigation dynamics.
What’s Still Unclear
- Whether the trial specifically centers on OpenAI’s fraud allegations or another related dispute is not fully clarified in the available details.
- Precise timing, venue specifics, and other procedural aspects of the trial beyond the ketamine exclusion are not provided.
- Broader implications for other high-profile tech or AI figures in similar cases have not been addressed in the sources.
- How the exclusion might affect strategy or witness testimony remains unspecified.
Context
General background on the topic: In high-profile technology and AI industry litigation, courts may draw limits on what personal information or medical history can be used as evidence. Such rulings aim to balance privacy, relevance, and the integrity of legal proceedings.
Why It Matters
This ruling underscores how courts manage sensitive personal information in complex tech disputes. The decision could influence how parties frame arguments about leadership, personal behavior, and organizational history in AI-related litigation.
What to Watch Next
- Watch for any further court rulings that refine admissible evidence in this case.
- Monitor updates on the scope of OpenAI’s fraud-related litigation and any changes in procedural rules affecting testimony.
- Follow media coverage for additional context on Musk’s involvement and related medical disclosures in the trial timeline.
FAQ
Q: What is being restricted in the trial?
A: Elon Musk’s use of ketamine is off limits to attorneys for OpenAI and its CEO Sam Altman during the upcoming jury trial.
Q: What is the trial about?
A: The trial involves claims that OpenAI defrauded Musk by abandoning its nonprofit roots; specific details about the case scope are not fully disclosed in the available information.
Related coverage
- 今日必读：美国能源部长闹乌龙致油价波动，北京对特朗普访华筹备草率表达不满，专家呼吁谨慎使用AI智能体 — 今日必读
- Apple AI delays smart home display
- Prediction market war contracts risks: CEO warns of
Source Transparency
- This article is based on a short preliminary brief and may not reflect the full details available in ongoing reporting.
- Source links are provided in the Sources section where available.
- A limited open-web check was used to clarify key details when possible; unclear items remain clearly marked.
Original brief: Elon Musk’s use of the drug ketamine will be off limits to attorneys for OpenAI and its CEO Sam Altman during an upcoming jury trial over claims that the generative AI company defrauded Musk by abandoning its nonprofit roots…
Sources
- Elon Musk's Ketamine Use Can't be Probed in OpenAI Fraud Trial
- Musk's Government Job Did Not Curb His Ketamine Habit – MSN
- Elon Musk's Ketamine Use Caused Bladder Problems: Report
- Elon Musk and Ketamine: A Dose of Science – Psychology Today
- “Ecstasy, mushrooms, ketamine” Musk denies massive drug use – and …